Is antipsychotic medication stigmatizing for people with mental illness?

International Review of Psychiatry

Volumn 19, Issue 2, 2007, Pages 107-112

  Sajatovic, Martha ^a,b   Jenkins, Janis H ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; RISPERIDONE;

AGE DISTRIBUTION; ARTICLE; ATTITUDE TO MENTAL ILLNESS; BIPOLAR DISORDER; DISEASE SEVERITY; DRUG SAFETY; DRUG WITHDRAWAL; ETHNICITY; FAMILY; HUMAN; MENTAL DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SELF ESTEEM; SEX DIFFERENCE; SOCIAL DISCRIMINATION; SOCIAL PSYCHIATRY; SOCIETY; STIGMA; SYMPTOM; TREATMENT OUTCOME; TREATMENT REFUSAL;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; PREJUDICE; PUBLIC OPINION; SCHIZOPHRENIA; STEREOTYPING; TREATMENT REFUSAL;

EID: 34247600547     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.1080/09540260701278911     Document Type: Article

References (31)

1. American Diabetes Association & American Psychiatric Association (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27, 596-561.
2. American Psychiatric Association (2002). Practice guideline for the treatment of patients with bipolar disorder (Revision). Washington, DC: American Psychiatric Press.
3. Awad, A. G. (1993). Subjective response to neuroleptics in schizophrenia. Schizophrenia Bulletin, 19(3), 609-618.
4. Awad, A. G., Voruganti, L. N., Keslegrave, R. J., & Hogan, T. P. (1996). Assessment of the patient's subjective experience in acute neuroleptic treatment: Implications for compliance and outcome. International Clinical Psychopharmacology, 11(Suppl 2), 55-59.
5. Camp, D. L., Finlay, W. M., & Lyons, E. (2002). Is low self-esteem an inevitable consequence of stigma? An example from women with chronic mental health problems. Social Science and Medicine, 55(5), 823-834.
6. Carrick, R., Mitchell, A., Powell, R. A., & Lloyd, K. (2004). The quest for well-being: A qualitative study of the experience of taking antipsychotic medication. Psychology and Psychotherapy: Theory, Research and Practice, 77, 19-33.
7. Citrome, L., Goldberg, J. F., & Stahl, S. M. (2005). Toward convergence in the medication treatment of bipolar disorder and schizophrenia. Harvard Review of Psychiatry, 13(1), 28-42.
8. Davidhizar, R. E. (1985). Can clients with schizophrenia describe feelings and beliefs about taking medication? Journal of Advanced Nursing, 10, 469-473.
9. Freudenreich, O., Cather, C., Evins, A. E., Henderson, D. C., & Goff, D. C. (2004). Attitudes of schizophrenia outpatient s toward psychiatric medications: Relationship to clinical variables and insight. Journal of Clinical Psychiatry, 65(10), 1372-1376.
10. Gaebel, W., Weinmann, S., Sartorius, N., Rutz, W., & McIntyre, J. S. (2005). Schizophrenia practice guidelines: International survey and comparison. British Journal of Psychiatry, 187, 248-255.
11. Ghaemi, S. N. (2000). New treatments for bipolar disorder: The role of atypical neuroleptic agents. Journal of Clinical Psyochiatry, 61(Suppl 14), 33-42.
12. Hayward, P., Wong, G., Bright, J. A., & Lam, D. (2002). Stigma and self-esteem in manic depression: An exploratory study. Journal of Affective Disorders, 69(1-3), 61-67.
13. Highet, N. J., McNair, B. G., Thompson, M., Davenport, T. A, & Hickie, I. B. (2004). Experience with treatment services for people with bipolar disorder. Medical Journal of Australia, 181(7 Suppl), S47-S51.
14. Hudson, T. J., Owen, R. R., Thrush, C. R., Han, X., Pyne, J. M., Thappa, R. et al. (2004). A pilot study of barriers to medication adherence in schizophrenia. Journal of Clinical Psychiatry, 65(2), 211-216.
15. Jenkins, J. H., & Carpenter-Song, E. (2005). The new paradigm of recovery from schizophrenia: Cultural conundrums of improvement without cure. Culture, Medicine and Psychiatry, 29(4), 379-413.
16. Jenkins, J. J., Strauss, M. E., Carpenter, E. A., Miller, D., Floersch, J., & Sajatovic, M. (2005). Subjective experience of recovery from schizophrenia-related disorders and atypical antipsychotics. International Journal of Social Psychiatry, 51(3), 211-217.
17. Katschnig, H. (2000). Schizophrenia and quality of life. Acta Psychiatrica Scandinavica Supplement, 407, 33-37.
18. Lee, S., Chiu, M.Y., Tsang, A., Chui, H., & Kleinman, A. (2006). Stigmatizing experience and structural discrimination associated with the treatment of schizophrenia in Hong Kong. Social Science and Medicine, 62(7), 1685-1696.
19. Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O. et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353(12), 1209-1223.
20. Loffler, W., Kilian, R., Toumi, M., & Angermeyer, M. C. (2003). Schizophrenic patient's subjective reasons for compliance and non-compliance with neuroleptic treatment. Pharmacopsychiatry, 36, 105-112.
21. Moore, A., Sellwood, W., & Stirling, J. (2000). Compliance and psychological reactance in schizophrenia. British Journal of Clinical Psychology, 39(Pt 3), 287-295.
22. Rudge, T., & Morse, K. (2004). Did anything change? Caregivers and schizophrenia after medication changes. Journal of Psychiatric and Mental Health Nursing, 11(1), 3-11.
23. Sajatovic, M., Jenkins, J. H., Safavi, R., West, J. A., Cassidy, K. A., Meyer, W. J., & Calabrese, J. R. Personal and societal construction of illness among individuals with rapid cycling bipolar disorder: A life trajectory perspective. American Journal of Geriatric Psychiatry (in press).
24. Sajatovic, M., Valenstein, M., Blow, F. C., Ganoczy, D., & Ignacio, R. V. (2006). Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disorder, 8(3), 232-241.
25. Simpson, G. M., Pi, E. H., & Sramek Jr, J. J. (1982). Management of tardive dyskinesia: Current update. Drugs, 23(5), 381-393.
26. Strejilevich, S., & Garcia Bonetto, G. (2003). Subjective responses to pharmacological treatments in bipolar patients. Journal of Affective Disorders, 77, 191-192.
27. Struening, E. L., Perlick, D. A., Link, B. G., Hellman, F., Herman, D., & Sirey, J. A. (2001). Stigma as a barrier to recovery: The extent to which caregivers believe most people devalue consumers and their families. Psychiatric Services, 52(12), 1633-1638.
28. Tsang, H. W., Tam, P. K., Chan, F., & Cheung, W. M. (2003). Sources of burdens on families of individuals with mental illness. International Journal of Rehabilitation Research, 26(2), 123-130.
29. Van Putten, T., May, P. R., Marder, S. R., & Wittmann, L. A. (1981). Subjective response to antipsychotic drugs. Archives of General Psychiatry, 38(20), 187-190.
30. Weiden, P., Rapkin, B., Mott, T., Zygmunt, A., Goldman, D., Horvitz-Lennon, M. et al (1994). Rating of medication influences (ROMI) scale in schizophrenia. Schizophrenia Bulletin, 20(2), 297-310.
31. Yassa, R. (1989). Functional impairment in tardive dyskinesia: Medical and psychosocial dimensions. Acta Psychiatrica Scandinavica, 80(1), 64-67.